INVITED INTERNATIONAL FACULTY
Ming-Lung YuKaohsiung Medical Univ., Taiwan
[June 11, 15:50-17:10] ROOM 1ABC
PG Course 4 [Chair]
Chronic Hepatitis B
Tetsuo TakeharaOsaka Univ., Japan
[June 11, 15:50-16:10] ROOM 1ABC
PG Course 4
Revisiting the Natural Course of Chronic Hepatitis B: Implications of the Indeterminate Phase
[June 12, 13:30-14:50] ROOM 1C
KASL Symposium 2 [Chair]
Autoimmune Liver Diseases and Beyond
Ju Dong Yang Cedars-Sinai Medical Center, USA
[June 11, 16:10-16:30] ROOM 1ABC
PG Course 4
Risk Stratification and Surveillance Strategies for HCC in Chronic Hepatitis B
[June 12, 14:30-14:50] ROOM 1AB
KASL-AASLD Joint Symposium
Rethinking HCC Surveillance in the MASLD Era: From Non-Cirrhotic Risk to Global Strategies
[June 13, 10:10-10:30] ROOM 2AB
KLCA Symposium 3
Multidisciplinary Horizons: From Immune Checkpoint Blockade to Liver Transplantation
Tung-Hung Su National Taiwan Univ., Taiwan
[June 11, 16:30-16:50] ROOM 1ABC
PG Course 4
Clinical Course and Management Considerations after Antiviral Therapy Discontinuation in Chronic Hepatitis B
[June 12, 15:10-15:30] ROOM 1AB
KASL Symposium 3
Personalizing Antiviral Therapy in Hepatitis B: Balancing Safety, Efficacy, and HCC Prevention
Edward GaneUniv. of Auckland, New Zealand
[June 11, 16:50-17:10] ROOM 1ABC
PG Course 4
Innovative Therapeutic Strategies for Functional Cure in HBV
[June 13, 09:30-09:50] ROOM 1C
KASL Symposium 6
Gene Therapies to Achieve Functional Cure in Chronic Hepatitis B
Jong-Hon KangTeine Keijinkai Hospital, Japan
[June 12, 07:30-08:00] ROOM 2C
KASL Branch Early Morning Workshop 1 [Gyeonggi-Incheon]
Clinical and Epidemiological Analysis of HEV Infection Based on the Nation-Wide Surveillance of Hepatitis E in Japan
Stefano Romeo Karolinska Institutet, Sweden
[June 12, 08:00-08:20] ROOM 2C
Translational Research 1
MASLD Phenotypic Diversity: From Genetic Discovery to Precision Medicine Stratification
[June 13, 09:10-09:30] ROOM 1AB
KASL Symposium 5
Outcomes and Prognosis in MASLD: Genetic Determinants from Single-Nucleotide Polymorphisms to Beyond
Tatsuya Kanto Japan Institute for Health Security, Japan
[June 12, 08:40-09:00] ROOM 2C
Translational Research 1
The Metabolic Triad in MASLD-MASH: Glucose, Lipid, and Amino Acid Dysregulation
[June 13, 13:10-13:50] ROOM 1AB
2026 KASL Clinical Practice Guidelines [Chair]
W. Ray KimMayo Clinic, USA
[June 12, 09:10-10:30] ROOM 1AB
KASL Symposium 1 [Chair]
Redefining the Natural History of Chronic Hepatitis B: Expanding Treatment Paradigms
[June 12, 13:30-13:50] ROOM 2C
Data Science Camp 1
Principles of Cohort Study Design: From Question to Data
[June 13, 08:00-09:00] ROOM 1C
KASL-AASLD Morning Workshop [Chair]
The Evolving Landscape of Liver Transplantation: From Policy to Practice
Nina Le BertDuke-NUS Medical School, Singapore
[June 12, 09:10-09:30] ROOM 1AB
KASL Symposium 1
Immunological Features of Chronic Hepatitis B: Stage-Specific Characteristics by Viremia Level
David A. BrennerSanford Burnham Prebys, USA
[June 12, 09:10-09:30] ROOM 2C
Translational Research 2
Hepatic Stellate Cell Activation and Fibrosis Reversal Mechanisms
[June 13, 10:50-11:20] ROOM 1AB
State-of-the-Art Lecture
Developing Drugs for Liver Fibrosis
Prashant BhanguiMedanta Institute, India
[June 12, 09:30-09:50] ROOM 3
KLTS Symposium 1
Downstaging to Transplant: Converting the Unresectable to the Transplantable
[June 12, 14:50-16:10] ROOM 3
KLTS Symposium 3 [Chair]
Liver Transplantation in the Era of MASLD
Yao-Chun HsuI-Shou Univ., Taiwan
[June 12, 09:50-10:10] ROOM 1AB
KASL Symposium 1
Impact of Antiviral Therapy in the Indeterminate Phase of Chronic Hepatitis B: Who Should Be Treated
[June 12, 15:30-15:50] ROOM 1AB
KASL Symposium 3
Discontinuation of Antiviral Therapy in Chronic Hepatitis B
Michael KarinSanford Burnham Prebys, USA
[June 12, 09:50-10:10] ROOM 2C
Translational Research 2
Senescent Hepatocytes as Tumor Seedbeds in MASH: Lessons from Single-Cell Maps
[June 12, 16:20-17:40] ROOM 2AB
KLCA Symposium 2 [Chair]
Managing MASLD-HCC: A Comprehensive Overview of Treatment Modalities and Strategies
[June 13, 14:20-14:50] ROOM 1C
Advances in Experimental Hepatology
At the Frontline of Metabolic Liver Disease: Stress and Inflammation
Yasuhito TanakaKumamoto Univ., Japan
[June 12, 10:10-10:30] ROOM 1AB
KASL Symposium 1
Latest Updates on Novel Biomarkers for Chronic Hepatitis B
Chien-Jen ChenGenomics Research Center, Taiwan
[June 12, 11:10-11:40] ROOM 1AB
President's Choice Lecture
From Clinic to Policy: A Physician's Journey toward Viral Hepatitis Eradication
[June 12, 16:20-16:40] ROOM 2C
Translational Hepatology
Promotion of Precision Health Using Molecular and Genomic Biomarkers in Liver Diseases
Toshimi KaidoSt. Luke's International Hospital, Japan
[June 12, 13:50-14:10] ROOM 3
KLTS Symposium 2
Prognostic Significance of Sarcopenia and Visceral Fat in Liver Transplant Recipients
Kathleen CoreyHarvard Medical School, USA
[June 12, 14:10-14:30] ROOM 1AB
KASL-AASLD Joint Symposium
Near-Future MASLD Therapies: Resmetirom, GLP-1 Receptor Agonists and Emerging Agents
Atsumasa Komori Nagasaki Univ., Japan
[June 12, 14:10-14:30] ROOM 1C
KASL Symposium 2
Treatment Optimization in Autoimmune Hepatitis: When First-Line Therapy Fails
Yu Jun WongDuke-NUS Medical School, Singapore
[June 12, 14:30-14:50] ROOM 1C
KLTS Symposium 2
Beyond Ursodeoxycholic Acid: The Next Chapter in Primary Biliary Cholangitis Treatment
[June 13, 14:30-14:50] ROOM 1AB
KASL Symposium 7
Achieving Recompensation in Cirrhosis: Evidence and Future Directions
Jia-Horng Kao National Taiwan Univ., Taiwan
[June 12, 14:50-16:10] ROOM 1AB
KASL Symposium 3 [Chair]
From Cure to Care: Remaining Challenges in HBV Management
Stephen Lam ChanThe Chinese Univ. of Hong Kong, Hong Kong
[June 12, 14:50-16:10] ROOM 2AB
KLCA-ILCA Joint Symposium [Chair]
Who Is the Best Partner for Anti-PD-1/PD-L1 in Advanced HCC: VEGF Inhibition vs. CTLA-4 Blockade
[June 13, 09:50-10:10] ROOM 2AB
KLCA Symposium 3
Novel Molecular and Cellular Therapies in HCC: The Next Wave
Antonio D'AlessioKing's College Hospital, UK
[June 12, 15:10-15:30] ROOM 2AB
KLCA-ILCA Joint Symposium
Anti-VEGF as a Partner to PD-L1 Blockade
[June 12, 16:20-17:40] ROOM 2AB
KLCA Symposium 2 [Chair]
Managing MASLD-HCC: A Comprehensive Overview of Treatment Modalities and Strategies
Seng-Gee LimNational Univ. of Singapore, Singapore
[June 12, 15:50-16:10] ROOM 1AB
KASL Symposium 3
Immune Mechanisms Driving HBsAg Decrease with Various Anti-HBV Therapeutics
[June 13, 13:50-15:10] ROOM 1AB
KASL Symposium 7 [Chair]
Liver Cirrhosis, Portal Hypertension, and Acute-on-Chronic Liver Failure (ACLF): Advancing the Continuum of Care from Organ Failure to Recovery
[June 13, 10:10-10:30] ROOM 1C
KASL Symposium 6
Endpoints of Chronic Hepatitis B Therapy: Partial, Functional, and Sterilizing Cure
Takumi KawaguchiKurume Univ., Japan
[June 12, 16:20-16:40] ROOM 1AB
KASL Symposium 4
Beyond Cure: Practical Care for Hepatitis C Patients with MASLD
Man-Fung YuenThe Univ. of Hong Kong, Hong Kong
[June 12, 16:20-17:40] ROOM 1AB
KASL Symposium 4 [Chair]
Management Strategies for Chronic Viral Hepatitis
[June 13, 09:10-09:30] ROOM 1C
KASL Symposium 6
Antisense Oligonucleotides vs. siRNA: Which Represents the Better Option for HBV Treatment?
Arndt Vogel Univ. of Toronto, Canada
[June 12, 16:40-17:00] ROOM 2AB
KLCA Symposium 2
Immunity and Resistance in MASLD-HCC: Strategies for Immune Checkpoint Inhibitor Therapy
Chun-Jen LiuNational Taiwan Univ., Taiwan
[June 12, 17:00-17:20] ROOM 1AB
KASL Symposium 4
Persistent Low-Level Viremia on Nucleos(t)ide Analogues in CHB Patients: Clinical Impact and Management Algorithms
Takahiro KodamaOsaka Univ., Japan
[June 12, 17:20-17:40] ROOM 2AB
KLCA Symposium 2
Tailoring Immunotherapy for MASLD-HCC: Challenges and Emerging Strategies
Fengqiang GaoZhejiang Univ., China
[June 12, 15:10-15:30] ROOM 3
KLTS Symposium 3
Outcomes and Risk Factors of Liver Transplantation Using Steatotic Grafts for HCC
Parissa TabrizianIcahn School of Medicine at Mount Sinai, USA
[June 13, 08:00-08:20] ROOM 1C
KASL-AASLD Morning Workshop
Expanding Donor Pool: Donation after Circulatory Death, Donation after Brain Death, and Ex-vivo Graft Management Strategies
Willscott NauglerOregon Health & Science Univ., USA
[June 13, 08:20-08:40] ROOM 1C
KASL-AASLD Morning Workshop
Optimizing Allocation and Policy Models: Balancing Equity and Efficiency: Opt-in vs. Opt-out Systems
Kiyoshi HasegawaThe Univ. of Tokyo, Japan
[June 13, 08:30-08:50] ROOM 3
KAHBPS Symposium 1
Surgical Considerations after Neoadjuvant or Conversion Therapy
Kei ShibuyaGunma Univ., Japan
[June 13, 09:10-09:30] ROOM 2AB
KLCA Symposium 3
Carbon Ion Therapy: The Next Step in Precision Radiotherapy
Maki SugimotoTeikyo Univ. Okinaga Research Institute, Japan
[June 13, 09:10-09:30] ROOM 3
KAHBPS Symposium 2
Augmented Reality for Preoperative Planning and Intraoperative Visualization
Daichi KitaguchiUniv. of Tsukuba, Japan
[June 13, 09:50-10:10] ROOM 3
KAHBPS Symposium 2
Real-Time AI Navigation in Minimally Invasive Surgery
Xin WangThe Chinese Univ. of Hong Kong, Hong Kong
[June 13, 10:10-10:30] ROOM 3
KAHBPS Symposium 2
Intraoperative Assessment and AI-Assisted Coaching System in Hepatobiliary Surgery
Tatiana KisselevaUniv. of California San Diego, USA
[June 13, 13:50-14:20] ROOM 1C
Advances in Experimental Hepatology
Reversibility of Activated Portal Fibroblast in Cholestatic Liver Fibrosis Regression
Rakhi MaiwallInstitute of Liver and Biliary Sciences, India
[June 13, 14:10-14:30] ROOM 1AB
KASL Symposium 7
Management of Acute Kidney Injury in ACLF: Current Evidence and Unmet Needs
